BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36401232)

  • 21. PARI functions as a new transcriptional target of FOXM1 involved in gastric cancer development.
    Zhang Y; Ye X; Chen L; Wu Q; Gao Y; Li Y
    Int J Biol Sci; 2018; 14(5):531-541. PubMed ID: 29805304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical prognostic value of A FOXM1 related long non-coding RNA expression in gastric cancer.
    Chong DQ; Shan JL; Yang CS; Wang R; Du ZM
    Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):417-421. PubMed ID: 29424899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The carcinogenic complex lncRNA FOXP4-AS1/EZH2/LSD1 accelerates proliferation, migration and invasion of gastric cancer.
    Chen RY; Ju Q; Feng LM; Yuan Q; Zhang L
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8371-8376. PubMed ID: 31646567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EZH2-mediated epigenetic suppression of EphB3 inhibits gastric cancer proliferation and metastasis by affecting E-cadherin and vimentin expression.
    Zhao K; He J; Wang YF; Jin SD; Fan Y; Fang N; Qian J; Xu TP; Guo RH
    Gene; 2019 Feb; 686():118-124. PubMed ID: 30408551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer.
    Tang B; Sun R; Wang D; Sheng H; Wei T; Wang L; Zhang J; Ho TH; Yang L; Wei Q; Huang H
    Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33593912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TEM1 expression in cancer-associated fibroblasts is correlated with a poor prognosis in patients with gastric cancer.
    Fujii S; Fujihara A; Natori K; Abe A; Kuboki Y; Higuchi Y; Aizawa M; Kuwata T; Kinoshita T; Yasui W; Ochiai A
    Cancer Med; 2015 Nov; 4(11):1667-78. PubMed ID: 26336878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pituitary tumor-transforming gene-1 serves as an independent prognostic biomarker for gastric cancer.
    Xu MD; Dong L; Qi P; Weng WW; Shen XH; Ni SJ; Huang D; Tan C; Sheng WQ; Zhou XY; Du X
    Gastric Cancer; 2016 Jan; 19(1):107-15. PubMed ID: 25627474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Positive Feedback Loop of lncRNA-
    Xu MD; Wang Y; Weng W; Wei P; Qi P; Zhang Q; Tan C; Ni SJ; Dong L; Yang Y; Lin W; Xu Q; Huang D; Huang Z; Ma Y; Zhang W; Sheng W; Du X
    Clin Cancer Res; 2017 Apr; 23(8):2071-2080. PubMed ID: 27756785
    [No Abstract]   [Full Text] [Related]  

  • 29. ADAM-17 expression is enhanced by FoxM1 and is a poor prognostic sign in gastric carcinoma.
    Fang W; Qian J; Wu Q; Chen Y; Yu G
    J Surg Res; 2017 Dec; 220():223-233. PubMed ID: 29180185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions.
    Inari H; Suganuma N; Kawachi K; Yoshida T; Yamanaka T; Nakamura Y; Yoshihara M; Nakayama H; Yamanaka A; Masudo K; Oshima T; Yokose T; Rino Y; Shimizu S; Miyagi Y; Masuda M
    BMC Cancer; 2017 Feb; 17(1):160. PubMed ID: 28241804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression of Forkhead box M1 protein associates with aggressive tumor features and poor prognosis of hepatocellular carcinoma.
    Sun HC; Li M; Lu JL; Yan DW; Zhou CZ; Fan JW; Qin XB; Tang HM; Peng ZH
    Oncol Rep; 2011 Jun; 25(6):1533-9. PubMed ID: 21431285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High expression of fibroblast-activating protein is a prognostic marker in non-small cell lung carcinoma.
    Yanagawa N; Sugai M; Shikanai S; Sugimoto R; Osakabe M; Uesugi N; Saito H; Maemondo M; Sugai T
    Thorac Cancer; 2022 Aug; 13(16):2377-2384. PubMed ID: 35818720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EZH2 promotes gastric cancer cells proliferation by repressing p21 expression.
    Xu J; Wang Z; Lu W; Jiang H; Lu J; Qiu J; Ye G
    Pathol Res Pract; 2019 Jun; 215(6):152374. PubMed ID: 30952377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CircGSK3B promotes RORA expression and suppresses gastric cancer progression through the prevention of EZH2 trans-inhibition.
    Ma X; Chen H; Li L; Yang F; Wu C; Tao K
    J Exp Clin Cancer Res; 2021 Oct; 40(1):330. PubMed ID: 34666800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancer of zeste homolog 2 exerts functions in gastric cancer development via modulating microRNA-222-3p methylation and WEE1 expression.
    Feng Y; Wang C; Shi T; Liu W; Liu H; Zhu B; Gao F
    Chem Biol Drug Des; 2022 Sep; 100(3):320-333. PubMed ID: 35765903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Correlation between expression of forkhead box M1 (FOXM1) and clinicopathological features and prognosis in patients with non-small cell lung cancer (NSCLC)].
    Liu YQ; Guo RH; Liu LK; Gao W; Zhu CJ; Wei J; Shu YQ
    Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):426-30. PubMed ID: 21875482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overexpression of Her-2 upregulates FoxM1 in gastric cancer.
    Qi W; Li X; Zhang Y; Yao R; Qiu W; Tang D; Liang J
    Int J Mol Med; 2014 Jun; 33(6):1531-8. PubMed ID: 24715000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Silencing forkhead box M1 promotes apoptosis and autophagy through SIRT7/mTOR/IGF2 pathway in gastric cancer cells.
    Yu W; Cui X; Wan Z; Yu Y; Liu X; Jin L
    J Cell Biochem; 2018 Nov; 119(11):9090-9098. PubMed ID: 29953672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FOXM1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer.
    Chu XY; Zhu ZM; Chen LB; Wang JH; Su QS; Yang JR; Lin Y; Xue LJ; Liu XB; Mo XB
    Acta Histochem; 2012 Dec; 114(8):755-62. PubMed ID: 22326401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High expressions of CD10, FAP and GPR77 in CAFs are associated with chemoresistance and worse prognosis in gastric cancer.
    Tong Y; Zhao Z; Zhang J; Wang W; Zhu Y
    Front Oncol; 2022; 12():984817. PubMed ID: 36387219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.